 Connection
David Camidge to Ipilimumab
This is a "connection" page, showing publications David Camidge has written about Ipilimumab.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.095 |
|
|
|
-
He K, Forde PM, Govindan R, Santoro A, Gettinger S, Borghaei H, Spira A, Chu Q, Zinner R, Schoenfeld AJ, Camidge DR, Spigel DR, Gurpide A, Juergens RA, Laurie SA, Cerra M, Spires T, Greenawalt DM, Rapoport I, Gainor JF. Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung). ESMO Open. 2026 Mar; 11(3):106078.
Score: 0.058
-
Ready NE, Ott PA, Hellmann MD, Zugazagoitia J, Hann CL, de Braud F, Antonia SJ, Ascierto PA, Moreno V, Atmaca A, Salvagni S, Taylor M, Amin A, Camidge DR, Horn L, Calvo E, Li A, Lin WH, Callahan MK, Spigel DR. Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. J Thorac Oncol. 2020 03; 15(3):426-435.
Score: 0.037
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|